We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+14.54%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.47B
AUM Growth
-$118M
Cap. Flow
-$497M
Cap. Flow %
-20.15%
Top 10 Hldgs %
35.06%
Holding
147
New
13
Increased
26
Reduced
28
Closed
38

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$70.1M
2
ADPT
Adeptus Health Inc
ADPT
+$48.6M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$22.8M
4
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$17.2M
5
XNPT
XENOPORT, INC.
XNPT
+$15.9M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$41.3M
2
NXTM
NxStage Medical Inc.
NXTM
+$32.2M
3
ELGX
Endologix Inc
ELGX
+$28.8M
4
GSK icon
GSK
GSK
+$24.8M
5
LOXO
Loxo Oncology, Inc
LOXO
+$22.5M

Sector Composition

Rank Sector Weight
1 Healthcare 68.33%
2 Financials 4.33%
3 Technology 0.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLUE
101
DELISTED
bluebird bio
BLUE
– –
-37,288
Closed -$41.3M
CAH icon
102
Cardinal Health
CAH
$53.5B
– –
-8,000
Closed -$615K
ESPR
103
DELISTED
Esperion Therapeutics
ESPR
– –
-32,970
Closed -$778K
EW icon
104
Edwards Lifesciences
EW
$49.4B
– –
-582,714
Closed -$13.8M
HALO icon
105
Halozyme
HALO
$9.23B
– –
-50,349
Closed -$676K
ILMN icon
106
Illumina
ILMN
$28.2B
– –
-11,308
Closed -$1.93M
NVAX icon
107
Novavax
NVAX
$1.35B
– –
-52,000
Closed -$7.35M
OFIX icon
108
Orthofix Medical
OFIX
$468M
– –
-360,459
Closed -$12.2M
PEN icon
109
Penumbra
PEN
$12.5B
– –
-100,000
Closed -$4.01M
PRQR icon
110
ProQR Therapeutics
PRQR
$240M
– –
-209,398
Closed -$3.05M
SEM
111
DELISTED
Select Medical
SEM
– –
-102,080
Closed -$593K
THC icon
112
Tenet Healthcare
THC
$16.8B
– –
-27,602
Closed -$1.02M
VRTX icon
113
Vertex Pharmaceuticals
VRTX
$123B
– –
-18,500
Closed -$1.93M
ATYR
114
aTyr Pharma
ATYR
$50M
– –
-32,966
Closed -$4.74M
ASXC
115
DELISTED
Asensus Surgical, Inc.
ASXC
– –
-4,755
Closed -$140K
NVTA
116
DELISTED
Invitae Corporation
NVTA
– –
-166,666
Closed -$1.2M
MRTX
117
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-110,049
Closed -$3.79M
NUVA
118
DELISTED
NuVasive, Inc.
NUVA
– –
-265,272
Closed -$12.8M
ISEE
119
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-10,000
Closed -$405K
SIOX
120
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-60,583
Closed -$6.26M
ARNA
121
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-464,088
Closed -$8.86M
KIN
122
DELISTED
Kindred Biosciences, Inc.
KIN
– –
-279,204
Closed -$1.45M
MNK
123
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-317,931
Closed -$20.3M
AKRX
124
DELISTED
Akorn Inc
AKRX
– –
-160,667
Closed -$4.58M
ELGX
125
DELISTED
Endologix Inc
ELGX
– –
-234,711
Closed -$28.8M
2 3 4
5
6

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q4 2015 Portfolio in Review

As of Q4 2015, Deerfield Management held 147 positions worth $2.47B, down 4.6% from $2.59B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Deerfield Management withdrew a net $497M in Q4 2015, closing 38 positions and reducing 28 holdings. Its most notable exit was bluebird bio, an estimated $41.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 69% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in Five Prime Therapeutics, Inc. worth $28.2M.

  • Deerfield Management's largest Q4 2015 buy was Five Prime Therapeutics, Inc.: 680,000 shares worth $28.2M.
  • Deerfield Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015, an estimated $70.1M increase.
  • Deerfield Management's biggest Q4 2015 reduction was NxStage Medical Inc., cutting an estimated $32.2M.
  • Deerfield Management fully exited bluebird bio in Q4 2015, selling an estimated $41.3M.
  • Deerfield Management's ten largest holdings make up 35% of its $2.47B portfolio in Q4 2015.
  • Deerfield Management opened 13 new positions and closed 38 in Q4 2015.
  • Deerfield Management's portfolio value fell 4.6% quarter-over-quarter to $2.47B.

Based on Deerfield Management's 13F filing for Q4 2015, filed 16 Feb 2016.